Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)
Status:
NOT_YET_RECRUITING
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
This is a Phase I, multicenter, non-randomized, open-label, dose-exploratory clinical study to evaluate the safety and tolerability of linperlisib combined with SHR2554 in the treatment of R/R PTCL, and to preliminary observe the antitumor efficacy of the combination of the two drugs.
Phase:
PHASE1
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China